Identification of c-erbB-3 binding sites for phosphatidylinositol 3'-kinase and SHC using an EGF receptor/c-erbB-3 chimera
about
Update on HER-2 as a target for cancer therapy: intracellular signaling pathways of ErbB2/HER-2 and family membersClass II phosphoinositide 3-kinases are downstream targets of activated polypeptide growth factor receptorsPhosphotyrosine-dependent interaction of SHC and insulin receptor substrate 1 with the NPEY motif of the insulin receptor via a novel non-SH2 domainThe phosphotyrosine interaction domain of Shc binds an LXNPXY motif on the epidermal growth factor receptorHeregulin-dependent regulation of HER2/neu oncogenic signaling by heterodimerization with HER3Transforming growth factor beta engages TACE and ErbB3 to activate phosphatidylinositol-3 kinase/Akt in ErbB2-overexpressing breast cancer and desensitizes cells to trastuzumabH-RYK, an unusual receptor kinase: isolation and analysis of expression in ovarian cancerEpidermal growth factor and betacellulin mediate signal transduction through co-expressed ErbB2 and ErbB3 receptorsNrdp1/FLRF is a ubiquitin ligase promoting ubiquitination and degradation of the epidermal growth factor receptor family member, ErbB3Recruitment of the class II phosphoinositide 3-kinase C2beta to the epidermal growth factor receptor: role of Grb2A tyrosine kinase profile of prostate carcinomaErbB3/HER3 intracellular domain is competent to bind ATP and catalyze autophosphorylationA comprehensive pathway map of epidermal growth factor receptor signalingPhosphotyrosine interactome of the ErbB-receptor kinase familyThe ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferationThe docking protein Gab1 is the primary mediator of EGF-stimulated activation of the PI-3K/Akt cell survival pathwayTyrosine kinase signalling in breast cancer: tyrosine kinase-mediated signal transduction in transgenic mouse models of human breast cancer.Evolution of CASK into a Mg2+-sensitive kinaseRegulation of ERBB3/HER3 signaling in cancerStructural analysis of the catalytically inactive kinase domain of the human EGF receptor 3Structure of the Pseudokinase VRK3 Reveals a Degraded Catalytic Site, a Highly Conserved Kinase Fold, and a Putative Regulatory Binding SiteComparative analysis of the Tyr-kinases CapB1 and CapB2 fused to their cognate modulators CapA1 and CapA2 from Staphylococcus aureusClinical Translation and Validation of a Predictive Biomarker for Patritumab, an Anti-human Epidermal Growth Factor Receptor 3 (HER3) Monoclonal Antibody, in Patients With Advanced Non-small Cell Lung Cancer.The mouse kinome: discovery and comparative genomics of all mouse protein kinasesThe cellular response to neuregulins is governed by complex interactions of the erbB receptor familyDiversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactionsA novel positive feedback loop mediated by the docking protein Gab1 and phosphatidylinositol 3-kinase in epidermal growth factor receptor signalingErbB-2 is a common auxiliary subunit of NDF and EGF receptors: implications for breast cancerControlled dimerization of ErbB receptors provides evidence for differential signaling by homo- and heterodimersThe ErbB signaling network: receptor heterodimerization in development and cancerErbB3 (HER3) interaction with the p85 regulatory subunit of phosphoinositide 3-kinase.Computational delineation of tyrosyl-substrate recognition and catalytic landscapes by the epidermal growth factor receptor tyrosine kinase domain.Engineered Multivalency Enhances Affibody-Based HER3 Inhibition and Downregulation in Cancer CellsErbB tyrosine kinases and the two neuregulin families constitute a ligand-receptor network.HER2/Neu tumorigenesis and metastasis is regulated by E2F activator transcription factors.Emerging therapies in gastrointestinal cancers.Mechanisms of activation of receptor tyrosine kinases: monomers or dimers.Heregulin-stimulated acetylcholine receptor gene expression in muscle: requirement for MAP kinase and evidence for a parallel inhibitory pathway independent of electrical activity.ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling.Elevated expression of activated forms of Neu/ErbB-2 and ErbB-3 are involved in the induction of mammary tumors in transgenic mice: implications for human breast cancer
P2860
Q21195197-41B60B25-FD71-4C3F-A376-101AF80AA6F8Q22254063-F981F208-B896-432B-AB3D-144EEB3D5C9CQ24307071-EF0E9CE6-0C68-41EF-928F-C237F613AC99Q24307577-C3D2295C-D5E4-44B7-9C11-B8BADAD9979DQ24309266-F5007C91-A86D-4C1A-B0E2-53CA704F8111Q24313194-E3912034-C646-4CF8-B399-953A2602ED23Q24313793-8ED8852A-D7F0-409C-8111-2F545111BC33Q24532786-7B019810-46B7-4B72-A252-F21E78A9C55FQ24538330-B6F13250-8928-4A97-BECC-D6DBBB9486E8Q24548332-2A1BB73B-6529-48E3-9F64-C44AA87A21D0Q24607795-D856839D-6849-43F2-8286-18F6ED38A129Q24621754-5CA07A0E-8CC2-463E-A22D-51BFA64B9DF9Q24672490-5CC0C6B1-82EE-48D2-B5DD-ED24905A546AQ24672516-0A0C9162-FD96-4EFF-840C-0447E0F9F2C3Q24678674-853BEA91-8731-4DFE-9327-DB0F23EFC037Q24799816-B5FF7F6D-61B2-4A15-8DA6-160795585EC7Q24803081-03C8779D-0BE2-492A-A320-029A93F500E5Q26269893-85DDDD7A-BAAF-45BB-8959-B391C3B7F208Q27024334-857F028B-A576-4ECC-A645-6C19FFD322F3Q27646596-7F157D72-B24D-46D6-95CB-5DCA469E8B43Q27653415-69926058-2E1E-4776-A250-513D1168E66EQ27680416-6CDB2D85-CF6E-40BD-8981-DA40C0A3A19EQ27853182-9C638111-25CD-4296-975E-78D45013B77FQ28588919-E4288522-3A81-46B0-8EC8-116B986D288FQ28609130-228D1871-27C3-405D-994C-FC7275705932Q28609149-CB614C5C-A7FB-4D3C-A7E2-BDFFA2116427Q28609913-D6115A17-2A21-4FB8-BB6D-77BA1F5E1E18Q28678776-C6E2BF96-633A-4E55-93AF-4D8615BAACFDQ28679173-37C023F9-22EB-4D5E-B0FD-0210831D64C1Q29617919-89228CFF-130E-417F-AC53-DCA22391D461Q30176115-E32F4DCB-0107-48FD-920A-A82574E3A864Q30581942-772DE3A6-A6CB-46C2-AC42-DC7524903D41Q33691823-26B7BB47-DDD9-4F87-BEB2-92E95890F1CBQ33781099-B6E9C5A0-F2D0-47FE-875C-929B0FC0AE78Q33794153-1048F201-F09C-4F67-9E64-E5408F6B1DCAQ33866870-40AEFF3F-79EC-4101-99CB-83A21841D9A5Q33883884-7ED422CB-0FC9-489C-B7B8-799F27523421Q33886118-0A8C4760-3985-45FD-9F98-15BA33A64A5EQ33886341-51D18A19-886E-446B-8BE3-4B147E71D2C0Q33890758-953B9907-CB41-41DA-8211-B12024E943D1
P2860
Identification of c-erbB-3 binding sites for phosphatidylinositol 3'-kinase and SHC using an EGF receptor/c-erbB-3 chimera
description
1994 nî lūn-bûn
@nan
1994 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
1994 թվականի հունիսին հրատարակված գիտական հոդված
@hy
1994年の論文
@ja
1994年論文
@yue
1994年論文
@zh-hant
1994年論文
@zh-hk
1994年論文
@zh-mo
1994年論文
@zh-tw
1994年论文
@wuu
name
Identification of c-erbB-3 bin ...... EGF receptor/c-erbB-3 chimera
@ast
Identification of c-erbB-3 bin ...... EGF receptor/c-erbB-3 chimera
@en
Identification of c-erbB-3 bin ...... EGF receptor/c-erbB-3 chimera
@nl
type
label
Identification of c-erbB-3 bin ...... EGF receptor/c-erbB-3 chimera
@ast
Identification of c-erbB-3 bin ...... EGF receptor/c-erbB-3 chimera
@en
Identification of c-erbB-3 bin ...... EGF receptor/c-erbB-3 chimera
@nl
prefLabel
Identification of c-erbB-3 bin ...... EGF receptor/c-erbB-3 chimera
@ast
Identification of c-erbB-3 bin ...... EGF receptor/c-erbB-3 chimera
@en
Identification of c-erbB-3 bin ...... EGF receptor/c-erbB-3 chimera
@nl
P2860
P3181
P1433
P1476
Identification of c-erbB-3 bin ...... EGF receptor/c-erbB-3 chimera
@en
P2093
S A Prigent
W J Gullick
P2860
P304
P3181
P407
P577
1994-06-15T00:00:00Z